Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200-Day Moving Average of $0.00

Akari Therapeutics PLC (NASDAQ:AKTX) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as low as $2.03. Akari Therapeutics shares last traded at $2.03, with a volume of 500 shares traded.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Akari Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 30th. B. Riley set a $7.00 target price on shares of Akari Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, ValuEngine upgraded shares of Akari Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 14th.

The company has a 50-day moving average price of $2.32. The firm has a market cap of $32.04 million, a price-to-earnings ratio of -11.88 and a beta of -2.89.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.16) EPS for the quarter. As a group, sell-side analysts predict that Akari Therapeutics PLC will post -1 EPS for the current fiscal year.

An institutional investor recently bought a new position in Akari Therapeutics stock. Virtu Financial LLC acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 39,864 shares of the biopharmaceutical company’s stock, valued at approximately $143,000. Virtu Financial LLC owned approximately 0.26% of Akari Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.90% of the company’s stock.

Akari Therapeutics Company Profile (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Featured Article: Elliott Wave Theory

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.